June 10, 2020 / 5:17 AM / a month ago

BRIEF-Pharnext To Begin Last PXT3003 Phase III Study Before End Q1-21

June 10 (Reuters) - PHARNEXT SA:

* PHARNEXT PROVIDES REGULATORY AND CLINICAL UPDATE ON PXT3003 PHASE III STUDY FOR THE TREATMENT OF CHARCOT-MARIE-TOOTH TYPE 1A

* PLANS TO INITIATE FINAL PIVOTAL PHASE III CLINICAL STUDY BEFORE END OF Q1 2021

* US FOOD AND DRUG ADMINISTRATION HAS AGREED WITH PHARNEXT AND PROVIDED CLEAR GUIDANCE ON REGULATORY PATHWAY TO APPROVAL FOR PXT3003 Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below